



## TO EVALUATE IMMUNOMODULATORY ACTIVITY OF ELEUSINE INDICA IN CYCLOPHOSPHAMIDE INDUCED IMMUNOSUPPRESSIVE WISTAR ALBINO RATS

Ankita Jotiram Godase\*, Shilpa Ajay Bhosale, Dipval Subhas Mane, Rohini Sadashiv Misal, Samruddhi Suhas Doshi, Ishwari Sidhwadkar, Kishori Jagtap

ADT's School of Pharmacy and Research Centre, Sharadanagar, Baramati 413115 Pune, Maharashtra, India

Corresponding author: **Ankita Jotiram Godase**

### Article History

Volume 6, Issue 12, 2024

Received: 30 May 2024

Accepted : 25 June 2024

Doi:

10.48047/AFJBS.6.S12.2024.1824-1839

### ABSTRACT

The objective of this study was to assess the immunomodulatory effects of *Eleusine indica* in Wistar albino rats with cyclophosphamide-induced immunosuppression. Wistar albino rats were divided into five groups, with each group comprising six rats. Group I served as the normal control, Group II received cyclophosphamide (20 mg/kg, i.p.) for 10 consecutive days, Group III received cyclophosphamide along with the standard drug levamisole (50 mg/kg, p.o.) for 10 consecutive days, Group IV received cyclophosphamide along with *Eleusine indica* extract (200 mg/kg, p.o.) for 10 consecutive days, and Group V received only *Eleusine indica* extract (200 mg/kg, p.o.) for 10 consecutive days. Following the treatment period, various immunological parameters such as hematological parameters, humoral immune response, and cell-mediated immune response were assessed. Cyclophosphamide administration led to a significant reduction in hematological parameters, humoral immune response, and cell-mediated immune response. However, treatment with *Eleusine indica* extract significantly mitigated these cyclophosphamide-induced alterations. Additionally, *Eleusine indica* extract exhibited immunostimulatory effects in normal rats. The findings of this study suggest that *Eleusine indica* possesses notable immunomodulatory properties and could serve as an adjunctive therapy in immunocompromised conditions.

**Key words** - *Eleusine Indica*, Immunomodulatory activity, Cyclophosphamide, Immunosuppression.

### INTRODUCTION

For the vast majority of people worldwide, medicinal plants remain the primary source of healthcare, and they have been integral to traditional medical systems since ancient times.

In Africa, the practice of healing with plants has endured for generations, with knowledge passed down orally among specific groups like herbalists and traditional healers. Researchers have identified over 814 species with therapeutic properties from 130 different plant groups. Among these, *Eleusine indica* holds significance as a medicinal plant in Benin. *Eleusine indica*, a member of the Poaceae family, is indigenous to tropical and subtropical regions and is commonly considered a weed species [1-4].


*E. indica* is believed to possess various pharmacological properties including anti-inflammatory, antioxidant, antibacterial, hepatoprotective, antiplasmodial, and antidiabetic effects. In Malaysia, *E. indica*, locally known as "rumput sambau," is the most accessible species of Eleusine and is commonly found growing along sidewalks and highways. Throughout history, traditional medicine has employed *E. indica* to address diverse conditions such as symptoms of microbial infections, muscle sprains, bloody coughs, and poisoning from scorpions or centipedes. Literature reviews indicate that traditional healers worldwide extensively use *E. indica* to manage conditions like inflammation and autoimmune disorders. Additionally, in India, young plant seedlings of *E. indica* are consumed either raw or cooked as a side dish with rice during periods of famine [5-8].

According to nutritional analysis, *E. indica* contains a variety of essential nutrients, including fibre, vitamins, minerals, proteins, lipids, and carbohydrates. *Eleusine indica* L., commonly known as goose grass, is a C4 grass that typically behaves as a summer annual in temperate climates. In turf grass systems, it can be particularly problematic in high-traffic areas where turf grass is less competitive. The immune system operates with a multi-layered defence mechanism. The initial line of defence against infections is provided by the skin, which serves as the most basic barrier.

Physiological barriers also come into play, altering environmental factors such as pH and temperature to create unsuitable conditions for non-native species. Upon entry of pathogens into the body, both the innate and adaptive (or acquired) immune systems are activated to combat them. These systems consist of various chemicals and cells that intricately interact to detect and eliminate infections [9-13].

1. The innate immune system
  - The complement system
  - Macrophages
  - Cytokines and natural killer cells
2. The adaptive immune system
3. Cytokines/ interleukins
4. C-reactive protein
5. Immunomodulators

**Factors associated with the modification of immune system [14, 15]**



**Fig. 1 Factors affecting immune system**

Cyclophosphamide (CP), a potent alkylating agent, is extensively utilized in chemotherapy to treat diverse cancers and autoimmune disorders. Although CP effectively targets rapidly dividing cells, such as cancer cells, its administration often results in immunosuppression. This immunosuppressive effect arises from CP's capability to disrupt the proliferation and functionality of immune cells, ultimately compromising the immune response and heightening susceptibility to infections [16-18].

In recent years, there has been a surge in interest regarding the exploration of natural products as potential immunomodulatory agents. These natural compounds present several advantages over conventional drugs, such as their favourable safety profile, minimal side effects, and ability to modulate the immune system without causing undue harm. *Eleusine indica*, commonly known as "goose grass" or "wiregrass," is a plant that has been traditionally utilized in various regions across the globe for its medicinal properties [19-22].

#### ***Eleusine indica***

*Eleusine indica* (L.) Gaertn, a perennial plant belonging to the Poaceae family, has been valued for its therapeutic properties for an extended period. It is predominantly found in the Pacific Islands and tropical regions. The most accessible species of *Eleusine* is *E. indica*, known locally as "rumput sambau" in Malaysia, and it tends to proliferate like a weed along sidewalks and roadways. Traditional medical practices across the globe have utilized *E. indica* to address various conditions, including symptoms of microbial infections, muscle injuries, bloody coughs, and incidents of scorpion or centipede poisoning [23, 24].



**Fig 2. *Eleusine indica***


**Taxonomy of *Eleusine indica***[25, 26]

**Table 1. Taxonomy of *Eleusine indica***

Common names	Wagnakhi, goose grass
Domain	Eukaryota
Kingdom	Plantae
Phylum	Spermatophyta
Subphylum	Angiospermae
Class	Monocotyledonae
Order	Cyperales
Family	Poaceae
Genus	<i>Eleusine</i>
Species	<i>Eleusine indica</i>

*Eleusine indica* has been reported to possess a wide range of pharmacological activities, including antioxidant, anti-inflammatory, antimicrobial, and immunomodulatory properties. However, its potential immunomodulatory effects, particularly in the context of CP-induced immunosuppression, remain relatively unexplored.

**Pharmacological properties of *Eleusine indica***



**Fig 3. Pharmacological properties of *Eleusine indica***

In this study, our objective was to examine the immunomodulatory effects of *Eleusine indica* in Wistar albino rats with cyclophosphamide-induced immunosuppression. We hypothesized that the extract of *Eleusine indica* would alleviate the immunosuppressive effects caused by cyclophosphamide. To investigate this hypothesis, we evaluated different aspects of the immune system, such as hematological parameters, immune organ indices, and specific immune responses, in rats treated with *Eleusine indica* extract subsequent to cyclophosphamide-induced immunosuppression [27-30].

**MATERIALS AND EQUIPMENTS[31-36]**

**Material for Animal Trial**

**Table 2. Requirement of Animals**

Sr. No	Species	Rat
1	Strain	Wistar Albino Rats
2	Sex	Male
3	Body weight range	200-250 gm
4	No. of animals	72

**Study Design**

Six animals in each group were used for this study, Extract was dosed as per standard protocol and animals were observed for signs and symptoms along with weekly Body weight. Collection of Sheep RBC - Sheep RBC (SRBC) were collected in saline, washed three times in phosphate buffered solution (PBS) and adjusted to a concentration of 0.5X10<sup>9</sup> cells/ml.

**Haemagglutination Antibody (HA) Titre:-**

**Table 3. Haemagglutination Antibody (HA) Titre**

Group	Name of Group	Dose	No. of Animals (Wistar rats)
1.	Control	Only vehicle for 21 days	6

2.	Change	Vehicle for 21 days and Cyclophosphamide 30mg/kg i.p. on 18th,19th & 20th day	6
3.	Standard	Levamisole 50 mg/kg p.o for 21 days and Cyclophosphamide 30mg/kg i.p on 18th, 19th & 20 <sup>th</sup> day	6
4.	Experimental -1 (Extract 1)	Extract-1 200 mg/kg p.o. for 21 days and Cyclophosphamide 30mg/kg i.p. on 18th, 19th & 20th day	6
5.	Experimental -2 (Extract 2)	Extract-2 400 mg/kg p.o. for 21 days and Cyclophosphamide 30mg/kg i.p. on 18th, 19th & 20th day.	6
6.	Experimental -2 (Extract 3)	Extract-2 600 mg/kg p.o. for 21 days and Cyclophosphamide 30mg/kg i.p. on 18th, 19th & 20th day.	6

#### **Carbon Clearance Assay (Phagocytic Response):-**

For a duration of 21 days, the rats received treatment with extracts and a standard drug. On the 21st day, the rats were administered an intravenous injection of 0.2 ml/animal Indian ink dispersion (pre-warmed at 37 °C) through the tail vein. Blood samples were collected at 0 and 15 minutes following the injection by retro-orbital puncture and placed in micro-centrifuge tubes.

Subsequently, 25µl of blood samples were added to 2 ml of 0.1% Na<sub>2</sub>CO<sub>3</sub> solution. The absorbance was measured at 660 nm using a UV-visible spectrophotometer. The rate of carbon clearance, also known as the phagocytic index (K), was calculated using the formula  $k = \text{Loge} (\text{OD1})$ .

#### **OBSERVATION AND RESULTS**

##### **1) Haemagglutination Antibody (HA) Titre**

- **Body Weight HA**




Fig 4. Body Weight HA

• HA Titer




Fig 5. HA Titre

- IL 6 HA




Fig 6. IL 6HA

- TNF HA




Fig 7. TNF HA

- CRP HA






Fig 8. CRP HA

2) Carbon Clearance Test

- Body Weight




Fig 9. Body weight CCT

- Phagocytic Index




Fig 10. Phagocytic Index CCT

- IL-6




Fig 11. IL-6 CCT

- TNF- $\alpha$




Fig 12. TNF-α CCT

- CRP




Fig 13. CRP CCT

## DISCUSSION

The objective of our study was to explore the immunomodulatory potential of Eleusine indica plant extract and its potential therapeutic applications. Our results indicate that Eleusine indica extract exhibits substantial immunomodulatory effects, underscoring its significance as a valuable resource in herbal medicine.

**Summary of Findings:** Our investigation revealed that Eleusine indica extract exerted notable effects on several immune parameters. These effects included increased cytokine production, enhanced lymphocyte proliferation, and heightened phagocytic activity. These positive outcomes suggest that Eleusine indica has the ability to modulate immune responses without specifically inducing either stimulation or suppression [37, 38].

The selection of Eleusine indica was based on several compelling reasons. Firstly, Eleusine indica, commonly known as goose grass, has been recognized for its significant medicinal value and has a long history of traditional use in diverse folk medicine practices across different cultures. Secondly, numerous studies have highlighted its potential medicinal properties, which include anti-inflammatory effects, antioxidant activity, wound healing properties, diuretic effects, and antimicrobial activity. Lastly, based on both scientific research and traditional medicinal uses, Eleusine indica was identified as a promising candidate for its anticipated immunomodulatory activity [39].

Eleusine indica is rich in various chemical constituents, including alkaloids, flavonoids, phenolic compounds, triterpenoids, saponins, and coumarins. These compounds contribute to

its diverse pharmacological activities, such as antioxidant, anti-inflammatory, and immunomodulatory properties.

Our study provides compelling evidence supporting the positive immunomodulatory activity of Eleusine indica plant extract. These findings underscore the potential of Eleusine indica as a valuable natural resource for maintaining immune balance and promoting overall health. However, further research is necessary to fully elucidate the mechanisms of action and therapeutic applications of Eleusine indica in immune modulation [40, 41].

**Hemagglutination Antibody (HA) Titre:** The hemagglutination test performed on Wistar albino rats provided valuable insights into the immunomodulatory potential of Eleusine indica. The observed increase in hemagglutination titres suggests enhanced antibody production, indicating an activated humoral immune response [42].

**Carbon Clearance Test:** The carbon clearance assay demonstrated the phagocytic response of the reticuloendothelial system to Eleusine indica extract. The results suggest that the extract may enhance the body's ability to clear foreign particles, indicating its potential in modulating immune function [43].

**C - reactive protein (CRP) Test:** Changes in CRP levels in rats treated with Eleusine indica extract suggest that the extract may influence the immune system by suppressing inflammation or stimulating immune responses [44].

**Interleukin-6 (IL-6) Test:** The IL-6 test showed alterations in IL-6 levels in rats treated with Eleusine indica extract, indicating its potential to modulate inflammatory responses or immune cell activity [45].

The findings of our study lend support to the potential immunomodulatory properties of Eleusine indica and emphasize its therapeutic promise in regulating immune function. Further research is warranted to delve into the mechanisms underlying these effects and to explore the potential applications of Eleusine indica in treating inflammatory and immune-related conditions. This ongoing investigation holds promise for uncovering new avenues for the development of novel therapies targeting immune dysregulation.

## CONCLUSION

From present Study it was concluded that Eleusine indica extract is safe in doses up to 400mg/kg and 600mg/kg and has good immunostimulant action when compared to the control group.

The immunostimulant activity is due to,

1. HA Titre
2. Phagocytic index
3. Proliferation of B cell

In the future, Eleusine indica holds potential as a candidate for cancer treatment due to its demonstrated immunostimulant activity. Additionally, its immunomodulatory properties suggest potential applications in combating infectious diseases. Continued research into the mechanisms of action and efficacy of Eleusine indica in these contexts may pave the way for its development as a therapeutic agent for cancer treatment and infectious diseases.

## REFERENCES

1. Sagnia B, Fedeli D, Casetti R, Montesano C, Falcioni G, Colizzi V. Antioxidant and anti-inflammatory activities of extracts from Cassia alata, Eleusine indica, Eremomastax speciosa, Carica papaya and Polyscias fulva medicinal plants collected in Cameroon. PloS one. 2014 Aug 4; 9(8):e103999.
2. Etame-Loe G, Ngoule CC, Mbome B, Pouka CK, Ngene JP, Yinyang J, Okalla C, Ngaba GP, Dibong SD. Contribution à l'étude des plantes médicinales et leurs utilisations traditionnelles dans le département du Lom et Djerem (Est, Cameroun). Journal of Animal & Plant Sciences. 2018;35(1):5560-78.

3. Haber RM, Semaan MT. Two new records from Lebanon: *Chamaesyce nutans* (Lag.) Small (Euphorbiaceae) and *Eleusine indica* (L.) Gaertner (Poaceae). *Turkish Journal of Botany*. 2007;31(4):341-3.
4. Al-Zubairi AS, Abdul AB, Abdelwahab SI, Peng CY, Mohan S, Elhassan MM. *Eleusine indica* possesses antioxidant, antibacterial and cytotoxic properties. *Evidence-Based Complementary and Alternative Medicine*. 2011 Jan 1;2011.
5. Kole C. *Wild crop relatives: genomic and breeding resources: millets and grasses*. Berlin/Heidelberg, Germany: Springer; 2011.
6. "W116 Goosegrass," The University of Tennessee Agricultural Extension Service, 06-0089, [https://trace.tennessee.edu/utk\\_agexcrop/109](https://trace.tennessee.edu/utk_agexcrop/109)
7. Okokon JE, Odomena CS, Effiong I, Obot J, Udobang JA. Antiplasmodial and antidiabetic activities of *Eleusine indica*. *International Journal of Drug Development and Research*. 2010;2(3):493-500.
8. De Melo, G.O., Muzitano, M.F., Legora-Machado, A., Almeida, T.A., De Oliveira, D.B., Kaiser, C.R., Koatz, V.L.G. and Costa, S.S., 2005. C-glycosylflavones from the aerial parts of *Eleusine indica* inhibit LPS-induced mouse lung inflammation. *Planta medica*, 71(04), pp.362-363.
9. Iqbal M, Gnanaraj C. *Eleusine indica* L. possesses antioxidant activity and precludes carbon tetrachloride (CCl<sub>4</sub>)-mediated oxidative hepatic damage in rats. *Environmental health and preventive medicine*. 2012 Jul;17:307-15.
10. Sukor NS, Zakri ZH, Rasol NE, Salim F. Annotation and Identification of Phytochemicals from *Eleusine indica* Using High-Performance Liquid Chromatography Tandem Mass Spectrometry: Databases-Driven Approach. *Molecules*. 2023 Mar 30;28(7):3111.
11. Boraschi D, Bossù P, Macchia G, Ruggiero P, Tagliabue A. Structure-function relationship in the IL-1 family. *Front Biosci*. 1996 Oct 1;1(1):270-308.
12. Arend WP, Malyak M, Guthridge CJ, Gabay C. Interleukin-1 receptor antagonist: role in biology. *Annual review of immunology*. 1998 Apr;16(1):27-55.
13. Dinarello CA. Overview of the IL-1 family in innate inflammation and acquired immunity. *Immunological reviews*. 2018 Jan;281(1):8-27.
14. Bachmann MF, Oxenius A. Interleukin 2: from immunostimulation to immunoregulation and back again. *EMBO reports*. 2007 Dec 1;8(12):1142-8.
15. Ghiasi H, Cai S, Slanina SM, Perng GC, Nesburn AB, Wechsler SL. The role of interleukin (IL)-2 and IL-4 in herpes simplex virus type 1 ocular replication and eye disease. *The Journal of infectious diseases*. 1999 May 1;179(5):1086-93.
16. Eder M, Geissler G, Ganser A. IL-3 in the clinic. *Stem cells*. 1997 Sep 1;15(5):327-33.
17. Frendl G. Interleukin 3: from colony-stimulating factor to pluripotent immunoregulatory cytokine. *International journal of immunopharmacology*. 1992 Apr 1;14(3):421-30.
18. Petes C, Mariani MK, Grandvaux N, Gee K. Interleukin (IL)-6 inhibits IL-27- and IL-30-mediated inflammatory responses in human monocytes. *Frontiers in immunology*. 2018 Feb 15;9:304983.
19. Bellelis P, Frediani Barbeiro D, Gueuvoghlian-Silva BY, Kalil J, Abrão MS, Podgaec S. Interleukin-15 and interleukin-7 are the major cytokines to maintain endometriosis. *Gynecologic and obstetric investigation*. 2019 Feb 1;84(5):435-44.
20. Belghith M, Bahrini K, Kchaou M, Maghrebi O, Belal S, Barbouche MR. Cerebrospinal fluid IL-10 as an early stage discriminative marker between multiple sclerosis and neuro-Behçet disease. *Cytokine*. 2018 Aug 1;108:160-7.

21. Couper KN, Blount DG, Riley EM. IL-10: the master regulator of immunity to infection. *The Journal of Immunology*. 2008 May 1;180(9):5771-7.
22. Jiang T, Huang Z, Zhang S, Zou W, Xiang L, Wu X, Shen Y, Liu W, Zeng Z, Zhao A, Zhou S. miR-23b inhibits proliferation of SMMC-7721 cells by directly targeting IL-11. *Molecular Medicine Reports*. 2018 Aug 1;18(2):1591-9.
23. Zhang JH, Zhang M, Wang YN, Zhang XY. Correlation between IL-4 and IL-13 gene polymorphisms and asthma in Uygur children in Xinjiang. *Experimental and therapeutic medicine*. 2019 Feb 1;17(2):1374-82.
24. Justiz Vaillant AA, Qurie A. Interleukin. [Updated 2022 Aug 22]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK499840/NBK499840>
25. Rincon M. Interleukin-6: from an inflammatory marker to a target for inflammatory diseases. *Trends in immunology*. 2012 Nov 1;33(11):571-7.
26. <https://images.app.goo.gl/SPKXesnqQs5dEiz68>
27. Behl T, Kumar K, Brisc C, Rus M, Nistor-Cseppento DC, Bustea C, Aron RA, Pantis C, Zengin G, Sehgal A, Kaur R. Exploring the multifocal role of phytochemicals as immunomodulators. *Biomedicine & Pharmacotherapy*. 2021 Jan 1;133:110959.
28. Yoshida T, Ichikawa J, Giuroiu I, Laino AS, Hao Y, Krogsgaard M, Vassallo M, Woods DM, Hodi FS, Weber J. C reactive protein impairs adaptive immunity in immune cells of patients with melanoma. *Journal for immunotherapy of cancer*. 2020;8(1).
29. Vermaelen K. Vaccine strategies to improve anti-cancer cellular immune responses. *Frontiers in immunology*. 2019 Jan 22;10:418373.
30. Hammerich L, Binder A, Brody JD. In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf. *Molecular oncology*. 2015 Dec 1;9(10):1966-81.
31. Ramanadham M, Nageshwari B. Anti-proliferative effect of levamisole on human myeloma cell lines in vitro. *Journal of Immunotoxicology*. 2010 Dec 1;7(4):327-32.
32. Ramanadham M, Nageshwari B. Anti-proliferative effect of levamisole on human myeloma cell lines in vitro. *Journal of Immunotoxicology*. 2010 Dec 1;7(4):327-32.
33. Larsen ES, Joensen UN, Poulsen AM, Goletti D, Johansen IS. Bacillus Calmette–Guérin immunotherapy for bladder cancer: a review of immunological aspects, clinical effects and BCG infections. *Apmis*. 2020 Feb;128(2):92-103.
34. Moorlag SJ, Arts RJ, Van Crevel R, Netea MG. Non-specific effects of BCG vaccine on viral infections. *Clinical microbiology and infection*. 2019 Dec 1;25(12):1473-8.
35. Safriani N, Rungkat FZ, Yuliana ND, Prangdimurti E. Immunomodulatory and antioxidant activities of select Indonesian vegetables, herbs, and spices on human lymphocytes. *International Journal of Food Science*. 2021 Mar 6;2021:1-2.
36. [https://en.m.wikipedia.org/wiki/Eleusine\\_indica](https://en.m.wikipedia.org/wiki/Eleusine_indica)
37. Lim TK. Edible medicinal and non-medicinal plants. Dordrecht, The Netherlands:: Springer; 2012.
38. Etebong EO, Ubulom PM, Obot D. A Systematic review on Eleusine indica (L.) Gaertn.: From ethnomedicinal uses to pharmacological activities. *Journal of Medicinal Plants*. 2020;8(4):262-74.
39. Zakri ZH, Suleiman M, Ng SY, Ngaini Z, Maili S, Salim F. Eleusine indica for Food and Medicine. *Journal Of Agrobiotechnology*. 2021 Sep 6;12(2):68-87.
40. Morah FN, Otuk ME. Antimicrobial and anthelmintic activity of eleusine indica. *Acta Sci et Intellectus*. 2015;2410:9738.
41. De Melo GO, Muzitano MF, Legora-Machado A, Almeida TA, De Oliveira DB, Kaiser CR, Koatz VL, Costa SS. C-glycosylflavones from the aerial parts of Eleusine

- indica inhibit LPS-induced mouse lung inflammation. *Planta medica*. 2005 Apr;71(04):362-3.
42. Nas JS. Evaluation of anticancer potential of Eleusine indica methanolic leaf extract through Ras-and Wnt-related pathways using transgenic *Caenorhabditis elegans* strains. *Journal of Pharmaceutical Negative Results*. 2020 Jan 30;11(1):42-6.
  43. Ibrahīm R, Yaacob WA, Ibrahim N. Phytochemistry, cytotoxicity and antiviral activity of Eleusine indica (sambau). In *AIP Conference Proceedings 2015 Sep 25* (Vol. 1678, No. 1). AIP Publishing.
  44. Malaguial PA, Maggay AK, Van Sibugan B, Salaban Q, Abusama H. Classroom experiments using phytochemical analysis of weed (eleusine indica). *Indonesian Journal of Multidisciplinary Research*. 2021;1(2):325-8.
  45. Boraschi D, Bossù P, Macchia G, Ruggiero P, Tagliabue A. Structure-function relationship in the IL-1 family. *Front Biosci*. 1996 Oct 1;1(1):270-308.